ABSTRACT
Cancer has always been a threat to society, one of the deadliest and third-largest deaths in the world being hepatocellular carcinoma (HCC). HCC has taken this awful rank, mostly due to multidrug resistance, late detection of the disease, elevated chemical-associated side effects, and higher risks of recurrence. The introduction of certain active compounds seems to be one of the main benefits of cancer prevention. Phytoactive action takes precedence over traditional chemotherapeutic drugs in the management of hepatocellular carcinoma in terms of their multi-target, multilevel and organized treatments. Literature recorded stupendous potential in inhibiting the initiation of HCC through molecular drug targeting, better bioavailability, important characteristic features of passive or active targeting, and stimulus-responsive drug release are achieved. Literature recorded stupendous potential in inhibiting the initiation of HCC through molecular drug targeting, better bioavail-ability, important characteristic features of passive or active targeting, and stimulus-responsive drug release are achieved. Thirdly, there are important advances in the HCC production of bioactive loaded nanocarriers and specialized nanocarriers. Remarkable findings were reported with respect to the clinical efficacy of HCC therapy with natural and nanocarrier chemicals. In addition, a significant examination of the presence of HCCs and the use of nanocarriers in the distribution of bioactive targeted active ingredients in HCC is essential.
